Nilanjan Ghosh

机构：University of Engineering & Management, Jadavpur University, Observer Research Foundation, Levine Cancer Institute · ORCID：0000-0002-3848-6136

发表论文 376 篇 · 总被引 10912 次 · h-index 43

代表论文

• Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet Oncology · 被引 50)
• Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab (2025 · Blood · 被引 38)
• Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study (2025 · Blood Advances · 被引 17)
• Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma (2025 · Blood Advances · 被引 8)
• How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives (2025 · Bone Marrow Transplantation · 被引 8)
• Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma (2026 · Blood · 被引 6)